立体定向放疗或转移灶切除术治疗寡转移性食管胃癌:一项全国性人群队列研究
该全国性人群队列研究纳入2015至2016年荷兰594例食管胃癌寡转移患者,比较局部治疗(立体定向放疗或转移灶切除术)与系统治疗的生存结局。结果显示,单纯局部治疗和局部联合系统治疗的中位总生存分别为16.0个月和22.7个月,均优于单纯系统治疗的8.5个月,且局部治疗与总生存改善独立相关。作者认为需随机对照试验证实这些结果。
要点
- 594例食管胃癌寡转移患者中,单纯局部治疗83例、局部联合系统治疗22例、单纯系统治疗489例。
- 中位总生存:单纯局部治疗16.0个月,局部联合系统治疗22.7个月,单纯系统治疗8.5个月。
- 局部治疗(单用或联合系统治疗)与总生存改善独立相关,HR分别为0.52和0.42。
核心结论
- 在荷兰这项人群队列研究中,与单纯系统治疗相比,寡转移灶局部治疗单用或联合系统治疗与总生存改善独立相关。
- 作者认为需随机对照试验证实这些结果。
研究设计与样本
- 荷兰全国性人群队列研究,纳入2015年至2016年所有食管胃癌伴同时性或异时性寡转移的患者。
- 寡转移定义为1个器官或1个区域外淋巴结区域的远处转移。
- 共纳入594例患者,其中单纯局部治疗83例、局部联合系统治疗22例、单纯系统治疗489例。
- 主要结局为总生存(从寡转移诊断起计算)及总生存的独立预后因素,采用多因素Cox比例风险模型分析。
主要发现
- 单纯局部治疗的中位总生存为16.0个月,局部联合系统治疗为22.7个月,单纯系统治疗为8.5个月。
- 与单纯系统治疗相比,单纯局部治疗与总生存改善独立相关(HR 0.52,95%CI 0.31-0.90)。
- 与单纯系统治疗相比,局部联合系统治疗与总生存改善独立相关(HR 0.42,95%CI 0.22-0.82)。
- 原发肿瘤控制与总生存改善独立相关(HR 0.48,95%CI 0.27-0.86)。
- 体能评分较差(HR 1.41,95%CI 1.32-1.75)、低分化或未分化肿瘤较高中分化肿瘤(HR 1.37,95%CI 1.06-1.76)、腹膜转移较淋巴结转移(HR 1.39,95%CI 1.00-1.93)与总生存恶化独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需随机对照试验证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: This nationwide population-based study analyzed the outcomes of local treatment (i.e. stereotactic body radiotherapy [SBRT] or metastasectomy) or systemic therapy for oligometastatic disease (OMD) in patients with esophagogastric cancer in The Netherlands. MATERIALS AND METHODS: Between 2015 and 2016, all patients in The Netherlands with esophagogastric cancer and synchronous or metachronous OMD were eligible for inclusion. Patients who underwent local treatment of OMD (SBRT or metastasectomy) and/or systemic therapy were included. OMD was defined as distant metastases in 1 organ or 1 extra-regional lymph node region. The primary outcomes were overall survival (OS) and independent prognostic factors for OS. OS was calculated from diagnosis of OMD. Prognostic factors for OS were analyzed using a multivariable Cox proportional hazard model. RESULTS: A total of 594 patients were included, of whom 83 underwent local treatment for OMD alone, 22 local treatment plus systemic therapy, and 489 systemic therapy alone. Median OS after local treatment for OMD alone was 16.0 months, local treatment plus systemic therapy 22.7 months, and after systemic therapy alone 8.5 months. Improved OS was independently associated with local treatment for OMD alone or combined with systemic therapy as compared with systemic therapy alone (hazard ratio [HR] 0.52, 95% CI: 0.31-0.90 and HR 0.42, 95% CI: 0.22-0.82, respectively) and a controlled primary tumor(HR 0.48, 95% CI: 0.27-0.86). Worse OS was independently associated with worse performance scores (HR 1.41, 95%: 1.32-1.75), poorly or undiffertumor as compared with good or moderadifferentiated tumor (HR 1.37, 95% CI: 1.06-1.76), and peritoneal as compared with lymph mode metastases (HR 1.39, 95% CI: 1.00-1.93). CONCLUSION: Local treatment of OMD alone or combined with systemic therapy was independently associated with improved OS as compared with systemic therapy alone in this population-based cohort study in The Netherlands. Randomized controlled trials are warranted to confirm these results.
引用
- Kroese TE, Jorritsma NKN, van Laarhoven HWM, et al. Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study. Clin Transl Radiat Oncol. 2022. PMID: 36186924. doi:10.1016/j.ctro.2022.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。